Chief Business Officer or Senior Vice President, Corporate Development
The company has a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a “do not eat” signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. By blocking this “do not eat” signal with decoy receptors, we aim to unmask tumor cells and make them visible to the immune system. Within this program Trillium has two decoy receptors (TTI-621 and TTI-622) that are currently being evaluated in patients with hematologic and solid tumors.
Trillium is building an impressive team led by President and CEO Jan Skvarka, PhD. Prior, Jan was President and Chief Executive Officer of Tal Medical, a clinical-stage neuroscience company in Boston, Massachusetts, from 2014 until 2018. Prior to that he had a long career from 1999 to 2013 as a healthcare consultant at Bain & Company, Boston. He was a partner in the Bain Healthcare practice from 2007 until 2013, with a focus on pharmaceutical, biotechnology and medical technology companies. Earlier in his career Jan worked in the corporate finance arm of Price Waterhouse in London, UK and Vienna, Austria. Jan holds an MBA degree from Harvard Business School.
Reporting to CEO, the Chief Business Officer/Senior Vice President, Corporate Development will be a major contributor in shaping the future success of Trillium Therapeutics. He/she will work closely with the CEO, executive management team and the Board of Directors to drive all business aspects of further evolution of the company towards late stage development and product commercialization.
Specifically, the CBO/SVP, Corp Dev will be responsible for corporate and business development activities, strategic planning, commercial input into clinical development and CMC, as well as supporting investor relationships.
The CBO/SVP, Corp Dev must have a broad business orientation and will have responsibility for the following:
- Corporate strategy: Work closely with the Chief Executive Officer (CEO) and members of the executive team and Board of Directors to define Trillium’s corporate vision and strategy for long-range planning, including corporate development strategy and partnering strategy
- Long-range operating plan: Design an executive business roadmap of potential business opportunities, including internal and external development programs, and financing opportunities
- Corporate development
- Business development: Lead the identification and evaluation of opportunities for in-licensing and out licensing
- Effectively present to pharma and biotechnology organizations the potential benefits of partnering or licensing with Trillium
- Negotiate significant company contracts, including licensing deals.
- Commercial input into clinical development and CMC
- Monitor competitive intelligence by keeping up to date on market trends, competitors and opportunities
- Support CEO in IR/PR activities
- Other special projects as directed by the CEO
- Negotiate significant company contracts, including licensing deals
- Provide regular presentations in various company forums including company and Board of Directors meetings. Ensure that all relevant supporting documentation for transactions (including external presentations, opportunity reports, management presentations, Board memos and other deal communication materials) are of the highest quality and are prepared, reviewed and approved as appropriate
- Cultivate a strong and effective partnership with R&D and clinical development teams to evaluate the potential new therapies and to integrate a commercial perspective early in the research and development process
- Over ten years of biopharma industry experience with at least five years of business development, corporate development, or strategic pipeline experience within the pharmaceuticals and biotechnology industry, identifying new products with in-licensing, out-licensing, and strategic partnering opportunities.
- Deep knowledge of the oncology, especially hematology/oncology market and treatment landscape in the US, and globally. At least three years of experience in oncology is preferred.
- Proven track record of identifying opportunities and, structuring, negotiating and closing transactions including strategic alliances, M&A, licensing agreements, joint ventures, equity investments, etc.
- In depth knowledge of financial analysis, corporate and product valuation as necessary to engineer such deals.
- Small/medium size biotech experience preferred but not critical
- Advanced scientific degree is preferred, MBA a plus
- Exceptional communication and influencing skills, with the ability to inspire confidence and work successfully with varied audiences including industry partners, financial institutions, Board of Directors, and colleagues.
- Strong executive presence.
- Entrepreneurial, collaborative, energetic self-starter with strong interpersonal and analytical skills and proven ability to work effectively with a CEO and other senior management as a strategic partner.
- Strong scientific orientation, ideally in oncology therapeutics. An ability to establish and maintain credibility with internal and external scientific and business experts.
- Desire to be part of a team and organization where patient focus, scientific and business excellence are shared values.
- Commitment to be a leader and culture builder.
How to Apply:
Please send your resume and cover letter to email@example.com with the title of the role in the subject line. Kindly note that phone calls and third parties are not accepted. Candidates must be authorized to work in the U.S.